Company profile · Biotech & medical
BRIM Biotechnology
全福生物科技股份有限公司 · 6885
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
BRIM Biotechnology develops new drugs using a translational science research model to develop new therapies that combat and cure diseases.[1]
The company's new drugs under development include BRM421 for dry eye, BRM424 for neurotrophic keratitis, BRM521 for osteoarthritis, BRM411 for glaucoma, and BRM412 for neovascular eye diseases.[2]
BRIM Biotechnology is based in Taipei, Taiwan.[1]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$1m | +74.9% | +19.6% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$19m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | BRIM Biotechnology, Inc. |
|---|---|
| Chinese name | 全福生物科技股份有限公司 |
| Stock code | 6885 (TWSE) |
| Industry | Biotech & medical |
| Founded | 31 Jul 2013 |
| Listed | 16 Dec 2024 |
| Paid-in capital | NT$1.3bn |
| Chairman | 林羣 |
| President | 徐文祺 |
| Headquarters | 8F, NO.1, Alley 30, Lane358, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan |
| Website | https://www.brimbiotech.com/ |
| Official business description | 新藥開發 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- MOPS 公司基本資料 全福生物科技股份有限公司 · mops · retrieved 04 Nov 2026
- BRIM全福生物科技股份有限公司 · website · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list